{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:09:04Z","timestamp":1788307744377,"version":"build-2803163510"},"reference-count":174,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.cytogfr.2020.11.001","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T14:20:12Z","timestamp":1606832412000},"page":"16-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["SARS-CoV-2: Targeted managements and vaccine development"],"prefix":"10.1016","volume":"58","author":[{"given":"Moiz","family":"Bakhiet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Taurin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cytogfr.2020.11.001_bib0005","series-title":"Coronavirus Disease (COVID-19): Weekly Epidemiological, Update 1","author":"World Health","year":"2020"},{"issue":"8","key":"10.1016\/j.cytogfr.2020.11.001_bib0010","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMp2000929","article-title":"A novel coronavirus emerging in China\u2014key questions for impact assessment","volume":"382","author":"Munster","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0015","series-title":"Reference Module in Life Sciences","article-title":"Human Coronavirus-229E, -OC43, -NL63, and -HKU1","author":"Liu","year":"2020"},{"issue":"26","key":"10.1016\/j.cytogfr.2020.11.001_bib0020","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1401505","article-title":"Evidence for camel-to-human transmission of MERS coronavirus","volume":"370","author":"Azhar","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"5643","key":"10.1016\/j.cytogfr.2020.11.001_bib0025","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1126\/science.1087139","article-title":"Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China","volume":"302","author":"Guan","year":"2003","journal-title":"Science"},{"issue":"7798","key":"10.1016\/j.cytogfr.2020.11.001_bib0030","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.cytogfr.2020.11.001_bib0035","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cell.2020.03.035","article-title":"A genomic perspective on the origin and emergence of SARS-CoV-2","volume":"181","author":"Zhang","year":"2020","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.cytogfr.2020.11.001_bib0040","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","article-title":"The proximal origin of SARS-CoV-2","volume":"26","author":"Andersen","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0045","doi-asserted-by":"crossref","DOI":"10.1007\/s13659-020-00250-4","article-title":"Natural products as potential leads against coronaviruses: could they be encouraging structural models against SARS-CoV-2?","author":"Orhan","year":"2020","journal-title":"Nat. Prod. Bioprospect."},{"issue":"10224","key":"10.1016\/j.cytogfr.2020.11.001_bib0050","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.cytogfr.2020.11.001_bib0055","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"2","key":"10.1016\/j.cytogfr.2020.11.001_bib0060","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0065","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2013.12.009","article-title":"The SARS coronavirus nucleocapsid protein--forms and functions","volume":"103","author":"Chang","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0070","doi-asserted-by":"crossref","DOI":"10.1126\/science.abb9983","article-title":"Site-specific glycan analysis of the SARS-CoV-2 spike","author":"Watanabe","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0075","series-title":"Geographic and Genomic Distribution of SARS-CoV-2 Mutations","author":"Mercatelli","year":"2020"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0080","article-title":"Increasing host cellular receptor-angiotensin-Converting enzyme 2 (ACE2) expression by coronavirus may facilitate 2019-nCoV (or SARS-CoV-2) infection","author":"Zhuang","year":"2020","journal-title":"J. Med. Virol."},{"issue":"6965","key":"10.1016\/j.cytogfr.2020.11.001_bib0085","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.cytogfr.2020.11.001_bib0090","doi-asserted-by":"crossref","first-page":"7988","DOI":"10.1073\/pnas.0409465102","article-title":"Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry","volume":"102","author":"Hofmann","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0095","article-title":"TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets","author":"Bestle","year":"2020","journal-title":"bioRxiv"},{"issue":"2","key":"10.1016\/j.cytogfr.2020.11.001_bib0100","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.cytogfr.2020.11.001_bib0105","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1073\/pnas.2002589117","article-title":"Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells","volume":"117","author":"Matsuyama","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.cytogfr.2020.11.001_bib0110","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1128\/JVI.00128-13","article-title":"The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies","volume":"87","author":"Gierer","year":"2013","journal-title":"J. Virol."},{"issue":"23","key":"10.1016\/j.cytogfr.2020.11.001_bib0115","doi-asserted-by":"crossref","first-page":"12552","DOI":"10.1128\/JVI.01890-13","article-title":"Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2","volume":"87","author":"Shirato","year":"2013","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.cytogfr.2020.11.001_bib0120","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1128\/JVI.02062-10","article-title":"A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry","volume":"85","author":"Shulla","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0125","article-title":"SARS-CoV-2 invades host cells via a novel route: CD147-spike protein","author":"Wang","year":"2020","journal-title":"bioRxiv"},{"issue":"3","key":"10.1016\/j.cytogfr.2020.11.001_bib0130","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s12015-020-09976-7","article-title":"CD147 as a target for COVID-19 treatment: suggested effects of azithromycin and stem cell engagement","volume":"16","author":"Ulrich","year":"2020","journal-title":"Stem Cell Rev. Rep."},{"issue":"3","key":"10.1016\/j.cytogfr.2020.11.001_bib0135","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.yexmp.2007.08.014","article-title":"CD147 immunoglobulin superfamily receptor function and role in pathology","volume":"83","author":"Iacono","year":"2007","journal-title":"Exp. Mol. Pathol."},{"issue":"7378","key":"10.1016\/j.cytogfr.2020.11.001_bib0140","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/nature10606","article-title":"Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum","volume":"480","author":"Crosnier","year":"2011","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.cytogfr.2020.11.001_bib0145","doi-asserted-by":"crossref","first-page":"6360","DOI":"10.1073\/pnas.111583198","article-title":"CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A","volume":"98","author":"Pushkarsky","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"10.1016\/j.cytogfr.2020.11.001_bib0150","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1128\/JVI.02168-09","article-title":"CD147\/EMMPRIN acts as a functional entry receptor for measles virus on epithelial cells","volume":"84","author":"Watanabe","year":"2010","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.cytogfr.2020.11.001_bib0155","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.cytogfr.2020.11.001_bib0160","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0092-8674(89)90124-4","article-title":"Characterization of an efficient coronavirus ribosomal frameshifting signal: requirement for an RNA pseudoknot","volume":"57","author":"Brierley","year":"1989","journal-title":"Cell"},{"issue":"6489","key":"10.1016\/j.cytogfr.2020.11.001_bib0165","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.cytogfr.2020.11.001_bib0170","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1042\/BCJ20200029","article-title":"Processing of the SARS-CoV pp1a\/ab nsp7-10 region","volume":"477","author":"Krichel","year":"2020","journal-title":"Biochem. J."},{"issue":"9","key":"10.1016\/j.cytogfr.2020.11.001_bib0175","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1371\/journal.pbio.0060226","article-title":"SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum","volume":"6","author":"Knoops","year":"2008","journal-title":"PLoS Biol."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","article-title":"Coronaviruses: an overview of their replication and pathogenesis","volume":"1282","author":"Fehr","year":"2015","journal-title":"Methods Mol. Biol."},{"issue":"18","key":"10.1016\/j.cytogfr.2020.11.001_bib0185","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10223","key":"10.1016\/j.cytogfr.2020.11.001_bib0190","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cytogfr.2020.11.001_bib0195","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1473-3099(20)30086-4","article-title":"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study","volume":"20","author":"Shi","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"10223","key":"10.1016\/j.cytogfr.2020.11.001_bib0200","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0205","first-page":"1","article-title":"Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children","author":"Rowley","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.cytogfr.2020.11.001_bib0210","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S2468-1253(20)30048-0","article-title":"Enteric involvement of coronaviruses: is faecal\u2013oral transmission of SARS-CoV-2 possible?","volume":"5","author":"Yeo","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0215","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)30528-6","article-title":"Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures","author":"Pung","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.cytogfr.2020.11.001_bib0220","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7326\/M20-0504","article-title":"The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application","volume":"172","author":"Lauer","year":"2020","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.cytogfr.2020.11.001_bib0225","doi-asserted-by":"crossref","first-page":"105924","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges","volume":"55","author":"Lai","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"12","key":"10.1016\/j.cytogfr.2020.11.001_bib0230","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMc2001737","article-title":"SARS-CoV-2 viral load in upper respiratory specimens of infected patients","volume":"382","author":"Zou","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.cytogfr.2020.11.001_bib0235","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41591-020-0869-5","article-title":"Temporal dynamics in viral shedding and transmissibility of COVID-19","volume":"26","author":"He","year":"2020","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.cytogfr.2020.11.001_bib0240","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(20)30196-1","article-title":"Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study","volume":"20","author":"To","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"9371","key":"10.1016\/j.cytogfr.2020.11.001_bib0245","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(03)13412-5","article-title":"Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study","volume":"361","author":"Peiris","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.cytogfr.2020.11.001_bib0250","doi-asserted-by":"crossref","first-page":"2001112","DOI":"10.1183\/13993003.01112-2020","article-title":"Association between age and clinical characteristics and outcomes of COVID-19","volume":"55","author":"Liu","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0255","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(20)30004-5","article-title":"Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study","author":"Chu","year":"2020","journal-title":"Lancet Microbe"},{"issue":"1","key":"10.1016\/j.cytogfr.2020.11.001_bib0260","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev.me.40.020189.002243","article-title":"Pulmonary surfactant","volume":"40","author":"Dobbs","year":"1989","journal-title":"Annu. Rev. Med."},{"issue":"2","key":"10.1016\/j.cytogfr.2020.11.001_bib0265","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11684-020-0754-0","article-title":"Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection","volume":"14","author":"Zou","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","author":"Monteil","year":"2020","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.cytogfr.2020.11.001_bib0275","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41591-020-0868-6","article-title":"SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes","volume":"26","author":"Sungnak","year":"2020","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.cytogfr.2020.11.001_bib0280","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nri.2016.58","article-title":"Inflammasomes: mechanism of assembly, regulation and signalling","volume":"16","author":"Broz","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0285","first-page":"ji2000513","article-title":"Inflammasomes and Pyroptosis as therapeutic targets for COVID-19","author":"Yap","year":"2020","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.cytogfr.2020.11.001_bib0290","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.138070","article-title":"Clinical and pathological investigation of patients with severe COVID-19","volume":"5","author":"Li","year":"2020","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.cytogfr.2020.11.001_bib0295","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1128\/JVI.01792-08","article-title":"Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells","volume":"83","author":"Yoshikawa","year":"2009","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.cytogfr.2020.11.001_bib0300","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1128\/JVI.74.7.3399-3403.2000","article-title":"Virus clearance through apoptosis-dependent phagocytosis of influenza A virus-infected cells by macrophages","volume":"74","author":"Fujimoto","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0305","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3389\/fcimb.2019.00241","article-title":"Innate immune recognition: an issue more complex than expected","volume":"9","author":"Kubelkova","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"9","key":"10.1016\/j.cytogfr.2020.11.001_bib0310","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.RES.0000187500.24964.7A","article-title":"Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients","volume":"97","author":"Keidar","year":"2005","journal-title":"Circ. Res."},{"issue":"3","key":"10.1016\/j.cytogfr.2020.11.001_bib0315","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.molimm.2008.10.022","article-title":"Angiotensin-(1-7) enhances angiotensin II induced phosphorylation of ERK1\/2 in mouse bone marrow-derived dendritic cells","volume":"46","author":"Nie","year":"2009","journal-title":"Mol. Immunol."},{"issue":"44","key":"10.1016\/j.cytogfr.2020.11.001_bib0320","doi-asserted-by":"crossref","first-page":"15748","DOI":"10.1073\/pnas.0403812101","article-title":"CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus","volume":"101","author":"Jeffers","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"21","key":"10.1016\/j.cytogfr.2020.11.001_bib0325","doi-asserted-by":"crossref","first-page":"12090","DOI":"10.1128\/JVI.78.21.12090-12095.2004","article-title":"DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus","volume":"78","author":"Marzi","year":"2004","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.cytogfr.2020.11.001_bib0330","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1128\/JVI.78.11.5642-5650.2004","article-title":"pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN","volume":"78","author":"Yang","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0335","article-title":"Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients","author":"Zhou","year":"2020","journal-title":"Sci. Rev."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0340","article-title":"Dysregulation of immune response in patients with COVID-19 in Wuhan, China","author":"Qin","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"SI-1","key":"10.1016\/j.cytogfr.2020.11.001_bib0345","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3906\/sag-2004-168","article-title":"COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs","volume":"50","author":"Tufan","year":"2020","journal-title":"Turk. J. Med. Sci."},{"issue":"48","key":"10.1016\/j.cytogfr.2020.11.001_bib0350","doi-asserted-by":"crossref","first-page":"eabd2071","DOI":"10.1126\/sciimmunol.abd2071","article-title":"Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome","volume":"5","author":"Weiskopf","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2020.04.023","article-title":"Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals","author":"Ni","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0365","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.thromres.2020.06.014","article-title":"COVID-19 and thrombotic complications: pulmonary thrombosis rather than embolism?","volume":"193","author":"Gabrielli","year":"2020","journal-title":"Thromb. Res."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0370","article-title":"Platelets can contain SARS-CoV-2 RNA and are hyperactivated in COVID-19","author":"Zaid","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0375","doi-asserted-by":"crossref","DOI":"10.1007\/s11239-020-02172-x","article-title":"Potential role for tissue factor in the pathogenesis of hypercoagulability associated with in COVID-19","author":"Bautista-Vargas","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"issue":"1","key":"10.1016\/j.cytogfr.2020.11.001_bib0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V71.1.1.1","article-title":"Tissue factor and hemostasis","volume":"71","author":"Nemerson","year":"1988","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cytogfr.2020.11.001_bib0385","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/ATVBAHA.107.141911","article-title":"Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis","volume":"27","author":"Mackman","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0390","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.15219","article-title":"Computer-aided assessment of the chemokine receptors CXCR3, CXCR4 and CXCR7 expression in gallbladder carcinoma","author":"Yu","year":"2020","journal-title":"J. Cell. Mol. Med."},{"issue":"2","key":"10.1016\/j.cytogfr.2020.11.001_bib0395","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.4081\/cp.2020.1271","article-title":"COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review","volume":"10","author":"Cavezzi","year":"2020","journal-title":"Clin. Pract."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0400","article-title":"Antibodies to SARS-CoV-2 are associated with protection against reinfection","author":"Lumley","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0405","article-title":"Reducing transmission of SARS-CoV-2","author":"Prather","year":"2020","journal-title":"Science"},{"issue":"6493","key":"10.1016\/j.cytogfr.2020.11.001_bib0410","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1126\/science.abb5793","article-title":"Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period","volume":"368","author":"Kissler","year":"2020","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.cytogfr.2020.11.001_bib0415","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.cytogfr.2020.11.001_bib0420","first-page":"e68","article-title":"A trial of Lopinavir-Ritonavir in Covid-19. Reply","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0425","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0430","doi-asserted-by":"crossref","first-page":"101738","DOI":"10.1016\/j.tmaid.2020.101738","article-title":"Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France","author":"Million","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"issue":"10229","key":"10.1016\/j.cytogfr.2020.11.001_bib0435","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cytogfr.2020.11.001_bib0440","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41421-020-0169-8","article-title":"The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro","volume":"6","author":"Wang","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105998","article-title":"Arbidol: a potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein","author":"Vankadari","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0450","article-title":"Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China","author":"Wang","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0455","article-title":"Efficacy and safety of Lopinavir\/Ritonavir or arbidol in adult patients with Mild\/Moderate COVID-19: an exploratory randomized controlled trial","author":"Li","year":"2020","journal-title":"Med"},{"issue":"9","key":"10.1016\/j.cytogfr.2020.11.001_bib0460","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40262-013-0072-7","article-title":"Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects","volume":"52","author":"Haschke","year":"2013","journal-title":"Clin. Pharmacokinet."},{"issue":"11","key":"10.1016\/j.cytogfr.2020.11.001_bib0465","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S2213-2600(20)30418-5","article-title":"Human recombinant soluble ACE2 in severe COVID-19","volume":"8","author":"Zoufaly","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.cytogfr.2020.11.001_bib0470","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"issue":"5","key":"10.1016\/j.cytogfr.2020.11.001_bib0475","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1096\/fj.202000919","article-title":"Rethinking the role of hydroxychloroquine in the treatment of COVID-19","volume":"34","author":"Meyerowitz","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0480","article-title":"Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results","author":"Pan","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0485","doi-asserted-by":"crossref","first-page":"104786","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro","author":"Choy","year":"2020","journal-title":"Antiviral Res."},{"issue":"19","key":"10.1016\/j.cytogfr.2020.11.001_bib0490","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of Lopinavir\u2013Ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.cytogfr.2020.11.001_bib0495","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jmii.2020.03.032","article-title":"Lopinavir\/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan","volume":"53","author":"Cheng","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"issue":"10","key":"10.1016\/j.cytogfr.2020.11.001_bib0500","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/infdis\/jiz656","article-title":"Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection","volume":"221","author":"Wang","year":"2020","journal-title":"J. Infect. Dis."},{"issue":"SI-1","key":"10.1016\/j.cytogfr.2020.11.001_bib0505","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3906\/sag-2004-145","article-title":"Antiviral treatment of COVID-19","volume":"50","author":"Simsek Yavuz","year":"2020","journal-title":"Turk. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.cytogfr.2020.11.001_bib0510","doi-asserted-by":"crossref","DOI":"10.1186\/s12985-020-01412-z","article-title":"Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis","volume":"17","author":"Shrestha","year":"2020","journal-title":"Virol. J."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with Favipiravir for COVID-19: an open-label control study","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0520","article-title":"Favipiravir versus arbidol for COVID-19: a randomized clinical trial","author":"Chen","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0525","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0530","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - final report","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0535","article-title":"A living WHO guideline on drugs for covid-19","volume":"370","author":"Lamontagne","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0540","article-title":"AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II\/III multicenter randomized clinical trial","author":"Ivashchenko","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.cytogfr.2020.11.001_bib0545","doi-asserted-by":"crossref","first-page":"e00754","DOI":"10.1128\/AAC.00754-20","article-title":"Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19","volume":"64","author":"Hoffmann","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.cytogfr.2020.11.001_bib0550","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/rth2.12357","article-title":"Fibrinolytic therapy for refractory COVID-19 acute respiratory distress syndrome: scientific rationale and review","volume":"4","author":"Barrett","year":"2020","journal-title":"Res. Pract. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.cytogfr.2020.11.001_bib0555","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40744-018-0102-x","article-title":"A review of recent advances using tocilizumab in the treatment of rheumatic diseases","volume":"5","author":"Rubbert-Roth","year":"2018","journal-title":"Rheumatol. Ther."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0560","article-title":"Serum concentrations of interleukin-6 (IL-6) in the general adult population: possible implications for anti-IL-6 therapy in SARS-Cov-2 infection and IL-6-related diseases","author":"Alende-Castro","year":"2020","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0565","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0570","article-title":"Tocilizumab in hospitalized patients with COVID-19 pneumonia","author":"Rosas","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0575","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.02132","article-title":"Cytokine storm in COVID-19: \"When you come out of the storm, you won\u2019t Be the same person who walked in","volume":"11","author":"Castelli","year":"2020","journal-title":"Front. Immunol."},{"issue":"7813","key":"10.1016\/j.cytogfr.2020.11.001_bib0580","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/d41586-020-01824-5","article-title":"Coronavirus breakthrough: dexamethasone is first drug shown to save lives","volume":"582","author":"Ledford","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.cytogfr.2020.11.001_bib0585","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(19)30417-5","article-title":"Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial","volume":"8","author":"Villar","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0590","article-title":"Dexamethasone in hospitalized patients with Covid-19-Preliminary report","author":"Horby","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.cytogfr.2020.11.001_bib0595","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1001\/jama.2020.16761","article-title":"Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial","volume":"324","author":"Dequin","year":"2020","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.cytogfr.2020.11.001_bib0600","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.2020.17022","article-title":"Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial","volume":"324","author":"Angus","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0605","doi-asserted-by":"crossref","first-page":"102850","DOI":"10.1016\/j.transci.2020.102850","article-title":"Anti-SARS-CoV-2 hyperimmune plasma workflow","author":"Annamaria","year":"2020","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0610","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc9999","article-title":"Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals","author":"Zhu","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0615","series-title":"Mayo Clinic Proceedings","article-title":"Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients","author":"Joyner","year":"2020"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0620","article-title":"SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19","author":"Chen","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7821","key":"10.1016\/j.cytogfr.2020.11.001_bib0625","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently neutralizing and protective human antibodies against SARS-CoV-2","volume":"584","author":"Zost","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0630","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe2402","article-title":"REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters","author":"Baum","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.tips.2020.07.004","article-title":"Fruitful neutralizing antibody pipeline brings hope to defeat SARS-Cov-2","author":"Renn","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"issue":"38","key":"10.1016\/j.cytogfr.2020.11.001_bib0640","doi-asserted-by":"crossref","first-page":"23652","DOI":"10.1073\/pnas.2008281117","article-title":"A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants","volume":"117","author":"Dearlove","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"50","key":"10.1016\/j.cytogfr.2020.11.001_bib0645","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.1016\/j.vaccine.2008.09.026","article-title":"A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial","volume":"26","author":"Martin","year":"2008","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.cytogfr.2020.11.001_bib0650","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/135965350701200702","article-title":"Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine","volume":"12","author":"Lin","year":"2007","journal-title":"Antivir. Ther."},{"issue":"2","key":"10.1016\/j.cytogfr.2020.11.001_bib0655","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.antiviral.2013.08.016","article-title":"Clinical management and infection control of SARS: lessons learned","volume":"100","author":"Cheng","year":"2013","journal-title":"Antiviral Res."},{"issue":"24","key":"10.1016\/j.cytogfr.2020.11.001_bib0660","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1001\/jama.2020.8920","article-title":"Accelerating COVID-19 therapeutic interventions and vaccines (ACTIV): an unprecedented partnership for unprecedented times","volume":"323","author":"Collins","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0665","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-020-00455-1","article-title":"Keeping track of the SARS-CoV-2 vaccine pipeline","author":"Parker","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0670","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial","author":"Xia","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0675","article-title":"Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial","author":"Zhang","year":"2020","journal-title":"medRxiv"},{"issue":"10","key":"10.1016\/j.cytogfr.2020.11.001_bib0680","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2020.15543","article-title":"Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials","volume":"324","author":"Xia","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0685","article-title":"Evaluation of safety and immunogenicity of an adjuvanted, TH-1 skewed, whole virion InactivatedSARS-CoV-2 vaccine - BBV152","author":"Ganneru","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0690","series-title":"Remarkable Immunogenicity and Protective Efficacy of BBV152, an Inactivated SARS-CoV-2 Vaccine in Rhesus Macaques","author":"Yadav","year":"2020"},{"issue":"10","key":"10.1016\/j.cytogfr.2020.11.001_bib0695","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.cytogfr.2020.11.001_bib0700","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.mayocp.2020.07.021","article-title":"SARS-CoV-2 vaccine development: current status","volume":"95","author":"Poland","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0705","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3389\/fphar.2020.01258","article-title":"Repurposing drugs, ongoing vaccine and new therapeutic development initiatives against COVID-19","volume":"11","author":"Saha","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"269","key":"10.1016\/j.cytogfr.2020.11.001_bib0710","article-title":"Vaccines through centuries: major cornerstones of global health","volume":"3","author":"Hajj Hussein","year":"2015","journal-title":"Front. Public Health"},{"issue":"2","key":"10.1016\/j.cytogfr.2020.11.001_bib0715","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/jama.282.2.137","article-title":"Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial","volume":"282","author":"Nichol","year":"1999","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.cytogfr.2020.11.001_bib0720","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41577-019-0261-1","article-title":"Rethinking mucosal antibody responses: IgM, IgG and IgD join IgA","volume":"20","author":"Chen","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.cytogfr.2020.11.001_bib0725","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1080\/21645515.2015.1114195","article-title":"Induction of mucosal immunity through systemic immunization: phantom or reality?","volume":"12","author":"Su","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0730","article-title":"Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with alum induces protective immunity and reduces immune enhancement","author":"Chen","year":"2020","journal-title":"bioRxiv"},{"issue":"7","key":"10.1016\/j.cytogfr.2020.11.001_bib0735","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.tplants.2020.04.009","article-title":"Potential applications of plant biotechnology against SARS-CoV-2","volume":"25","author":"Capell","year":"2020","journal-title":"Trends Plant Sci."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0740","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","author":"Keech","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0745","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.abst.2020.08.001","article-title":"Biomarkers of COVID-19 and technologies to combat SARS-CoV-2","volume":"2","author":"Zhang","year":"2020","journal-title":"Adv. Biomarker Sci. Technol."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0750","article-title":"Merck, one of Big Pharma\u2019s biggest players, reveals its COVID-19 vaccine and therapy plans","author":"Cohen","year":"2020","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.cytogfr.2020.11.001_bib0755","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.copbio.2007.10.010","article-title":"Replicating and non-replicating viral vectors for vaccine development","volume":"18","author":"Robert-Guroff","year":"2007","journal-title":"Curr. Opin. Biotechnol."},{"issue":"10255","key":"10.1016\/j.cytogfr.2020.11.001_bib0760","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"issue":"7830","key":"10.1016\/j.cytogfr.2020.11.001_bib0765","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"issue":"10249","key":"10.1016\/j.cytogfr.2020.11.001_bib0770","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0775","article-title":"Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1\/2a, double-blind, randomized, placebo-controlled trial","author":"Sadoff","year":"2020","journal-title":"medRxiv"},{"issue":"10249","key":"10.1016\/j.cytogfr.2020.11.001_bib0780","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"issue":"4949","key":"10.1016\/j.cytogfr.2020.11.001_bib0785","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"issue":"25","key":"10.1016\/j.cytogfr.2020.11.001_bib0790","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1056\/NEJMcibr2009737","article-title":"Amplifying RNA vaccine development","volume":"382","author":"Fuller","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.cytogfr.2020.11.001_bib0795","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","article-title":"mRNA as a transformative technology for vaccine development to control infectious diseases","volume":"27","author":"Maruggi","year":"2019","journal-title":"Mol. Ther."},{"issue":"7830","key":"10.1016\/j.cytogfr.2020.11.001_bib0800","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0805","article-title":"RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study","author":"Walsh","year":"2020","journal-title":"medRxiv"},{"issue":"7830","key":"10.1016\/j.cytogfr.2020.11.001_bib0810","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"issue":"6510","key":"10.1016\/j.cytogfr.2020.11.001_bib0815","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.abd0826","article-title":"Structure-based design of prefusion-stabilized SARS-CoV-2 spikes","volume":"369","author":"Hsieh","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0820","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 \u2014 preliminary report","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0825","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","author":"Anderson","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.cytogfr.2020.11.001_bib0830","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113605","article-title":"DNA vaccines-how far from clinical use?","volume":"19","author":"Hobernik","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.cytogfr.2020.11.001_bib0835","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.gt.3302213","article-title":"Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation","volume":"11","author":"Wang","year":"2004","journal-title":"Gene Ther."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0840","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583077","article-title":"Emerging concepts and technologies in vaccine development","volume":"11","author":"Brisse","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2020.11.001_bib0845","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/s41467-020-16505-0","article-title":"Immunogenicity of a DNA vaccine candidate for COVID-19","volume":"11","author":"Smith","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0850","article-title":"Cryo-EM structure of the SARS-CoV-2 3a ion channel in lipid nanodiscs","author":"Kern","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0855","article-title":"SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is further increased by a naturally occurring elongation variant","author":"Konno","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0860","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00711-20","article-title":"An 81 nucleotide deletion in SARS-CoV-2 ORF7a identified from sentinel surveillance in Arizona (jan-Mar 2020)","author":"Holland","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0865","series-title":"Coronavirus Nsp2 Protein Homologies to the Bacterial DNA Topoisomerase I and IV Suggest Nsp2 Protein Is a Unique RNA Topoisomerase With Novel Target for Drug and Vaccine Development","author":"CHAKRABORTY","year":"2020"},{"key":"10.1016\/j.cytogfr.2020.11.001_bib0870","first-page":"1","article-title":"The proteins of severe acute respiratory syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the cause of COVID-19","author":"Yoshimoto","year":"2020","journal-title":"Protein J."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610120302276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610120302276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T10:57:53Z","timestamp":1761217073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610120302276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":174,"alternative-id":["S1359610120302276"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2020.11.001","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SARS-CoV-2: Targeted managements and vaccine development","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2020.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}